2m 2m 2m 2m 2m 2m 2m
- $121.1MMarket Cap
- -46.78%1-Year Change
- Medical DevicesIndustry
QUANTERIX (QTRX)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 21
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
09/04/2026, 5:48 AM • GlobeNewswire
The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.
08/27/2026, 1:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 09/11/2026
Company Profile
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Key Executives
- Everett V. Cunningham
- Jason Faessler
- William Donnelly
- David R. Walt
- Jerzy Olejnik
Current Ownership Distribution
- Institutions629.9M (73.25%)
- Mutual Funds218.4M (25.40%)
- Insiders11.6M (1.35%)
- Other0 (0.00%)